Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
Signe SchmidtChristian S FrandsenThomas Fremming DejgaardDorte VistisenThórhallur HalldórssonSjudur F OlsenJens-Erik B JensenSten MadsbadHenrik U AndersenKirsten NørgaardPublished in: Diabetes, obesity & metabolism (2021)
Liraglutide lowered fat and lean body mass compared with placebo. Further, liraglutide reduced intake of added sugars. However, no significant difference in total daily energy intake was detected between liraglutide- and placebo-treated participants.
Keyphrases
- body composition
- type diabetes
- weight gain
- bone mineral density
- resistance training
- glycemic control
- physical activity
- double blind
- adipose tissue
- cardiovascular disease
- weight loss
- body mass index
- clinical trial
- phase iii
- newly diagnosed
- randomized controlled trial
- fatty acid
- postmenopausal women
- open label
- study protocol